Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild-to-Moderate COVID-19 Clear all
Completed Not applicable Interventional

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

NCT04486482
View directory record Official record
Conditions
Mild-to-Moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Cullman, Alabama • Los Angeles, California • Rancho Cucamonga, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

NCT04524663
View directory record Official record
Conditions
Covid19
Interventions
Camostat Mesilate, Placebo, Standard of Care Treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 29, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

NCT04896606
View directory record Official record
Conditions
Covid19
Interventions
Standard of Care, SARS-CoV2-CTLS
Other · Biological
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Valhalla, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

NCT05164120
View directory record Official record
Conditions
COVID-19
Interventions
Belnacasan, Placebo
Drug
Lead sponsor
MedStar Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, LY3832479, LY3853113, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Redondo Beach, California • Miami, Florida • Union City, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT04305457
View directory record Official record
Conditions
Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Shreveport, Louisiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
127
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT04880109
View directory record Official record
Conditions
COVID-19
Interventions
APX-115, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Withdrawn Phase 2 Interventional

iNOPulse for COVID-19

NCT04398290
View directory record Official record
Conditions
COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions
Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
Drug
Lead sponsor
Roger Alvarez
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

NCT04779879
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab (Gen1), Sotrovimab (Gen2)
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

NCT05941793
View directory record Official record
Conditions
Mild to Moderate COVID-19
Interventions
MBS-COV, Placebo
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

NCT04800120
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Taunton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 29, 2026, 6:59 PM EDT